PT Kalbe Farma Tbk (PTKFY) AI Stock Analysis

PT Kalbe Farma Tbk

(Other OTC:PTKFY)

Select Model

Rating:67Neutral

Price Target:$8.50▲(5.52% Upside)

Action:downgraded

Date:08/06/26

The score is driven mainly by strong financial performance and a conservative balance sheet, with valuation also supportive. The main drag is weaker technical momentum, as the stock remains below longer-term moving averages and MACD is negative. Earnings call and corporate events were excluded because no usable data was provided.

Positive Factors

Very low leverageThe exceptionally low debt burden gives Kalbe Farma substantial financial flexibility and reduces exposure to refinancing and interest-cost pressure. This supports continued investment in products and distribution while helping the company remain resilient if operating conditions weaken.

Negative Factors

Margin compressionAlthough profitability remains solid, the downward movement in gross, net, EBIT, and EBITDA margins indicates that earlier profitability levels are not being fully maintained. If this trend persists, it could constrain earnings growth even while revenue continues to expand.

PT Kalbe Farma Tbk (PTKFY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $8.97M
Dividend Yield: 2.48%
Average Volume (3M): 5,462
Price to Earnings (P/E): 9.2
Beta (1Y): 0.62
Revenue Growth: 7.85%
EPS Growth: 2.38%
Country: US
Employees: 12,835
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

PT Kalbe Farma Tbk Business Overview & Revenue Model

Company Description

PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescr...

PT Kalbe Farma Tbk Financial Statement Overview

Summary

Strong overall fundamentals support the score: revenue and profits have grown steadily, margins remain healthy, and the balance sheet is conservative with very low leverage. Cash flow is positive and supportive, but some volatility and recent margin pressure keep this from scoring higher.

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

72Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	37.91T	35.32T	32.63T	30.45T	28.93T	26.26T
Gross Profit	14.12T	14.06T	12.96T	11.82T	11.70T	11.28T
EBITDA	5.50T	5.60T	5.08T	4.41T	5.25T	4.87T
Net Income	3.63T	3.66T	3.24T	2.77T	3.38T	3.18T
Balance Sheet
Total Assets	33.21T	30.70T	29.43T	27.06T	27.24T	25.67T
Cash, Cash Equivalents and Short-Term Investments	5.01T	4.49T	4.87T	3.40T	4.10T	6.48T
Total Debt	829.84B	297.28B	559.22B	618.54B	1.17T	626.16B
Total Liabilities	7.34T	5.97T	4.84T	3.94T	5.14T	4.40T
Stockholders Equity	24.43T	23.31T	22.79T	21.42T	20.39T	19.58T
Cash Flow
Free Cash Flow	2.50T	2.46T	3.53T	1.73T	2.90T	1.83T
Operating Cash Flow	3.39T	3.27T	4.79T	2.91T	3.77T	2.83T
Investing Cash Flow	-1.25T	-799.89B	-1.25T	-1.14T	-1.37T	-1.06T
Financing Cash Flow	-1.17T	-2.87T	-2.09T	-2.44T	-2.41T	-745.18B

PT Kalbe Farma Tbk Technical Analysis

Technical Analysis SentimentNegative

Last Price8.05

Price Trends

50DMA8.43Negative

100DMA8.40Negative

200DMA9.80Negative

Market Momentum

MACD-0.14Negative

RSI48.07Neutral

STOCH89.85Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTKFY, the sentiment is Negative. The current price of 8.05 is below the 20-day moving average (MA) of 8.18, below the 50-day MA of 8.43, and below the 200-day MA of 9.80, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 48.07 is Neutral, neither overbought nor oversold. The STOCH value of 89.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTKFY.

PT Kalbe Farma Tbk Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PTKFY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
SNY	71Outperform	$106.82B	24.39	5.52%	5.46%	23.68%	-30.90%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
PTKFY	67Neutral	$1.88B	9.17	15.21%	2.48%	7.85%	2.38%
GSK	67Neutral	$99.56B	17.18	24.64%	3.67%	6.93%	-18.14%
OGN	53Neutral	$3.63B	17.52	22.11%	0.58%	-3.21%	-58.19%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

PTKFY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PTKFY	PT Kalbe Farma	8.05	-6.70	-45.42%
GSK	GlaxoSmithKline	49.51	4.72	10.55%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
PFE	Pfizer Inc	30.52	7.48	32.45%
SNY	Sanofi SA	44.34	-3.79	-7.87%
OGN	Organon & Co.	13.84	7.18	107.96%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 06, 2026

PT Kalbe Farma Tbk AI Stock Analysis